# Efficacy and Safety Evaluation of SMO1 in Patients With Retinal Vein Occlusive Macular Edema

> **NCT07708142** · PHASE3 · RECRUITING · sponsor: **SANGMYUNG innovation** · enrollment: 312 (estimated)

## Conditions studied

- Retinal Vein Occlusion With Macular Edema

## Interventions

- **DRUG:** Reference Drug
- **DRUG:** SMO1

## Key facts

- **NCT ID:** NCT07708142
- **Lead sponsor:** SANGMYUNG innovation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-29
- **Primary completion:** 2027-07
- **Final completion:** 2028-01
- **Target enrollment:** 312 (ESTIMATED)
- **Last updated:** 2026-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07708142

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07708142, "Efficacy and Safety Evaluation of SMO1 in Patients With Retinal Vein Occlusive Macular Edema". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07708142. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*